ERISA

ERISA Co., Ltd. is a Japanese biotech startup specializing in AI-driven diagnostic support systems for neurological and psychiatric disorders. Founded in 2017 as a spin-off from Shimane University, the company develops software that analyzes brain MRI images to predict and diagnose conditions such as Alzheimer's disease, dementia, and depression. Its flagship product, BAAD (Brain Anatomical Analysis and Diagnosis), quantifies brain atrophy in specific regions to assist clinicians in objective assessment. ERISA's technology aims to enable early detection and prevention of dementia through its SupportBrain risk prediction program. The company is active in Japan, China, and Vietnam, collaborating with medical institutions and research centers to advance brain health monitoring.